Introduction
Leber's congenital amaurosis-2 (LCA2), one of the earliest and most severe forms of inherited retinal dystrophies, 1 has been linked to mutations in Rpe65, a gene whose protein product, RPE65 (retinal pigment epithelium specific 65 kDa protein) is crucial in the visual cycle. It restores light sensitivity to the retina by enzymatically converting the all-trans-isomer to its light active 11-cis form. Although much is known about the retinoid cycle and RPE65 as it pertains to rod photoreceptors, less is known about its role in cones. However, recent studies suggest a clear dependency of cones on this isomerase activity, [2] [3] [4] [5] and LCA2 patients show early foveal cone loss. 6 Importantly, these patients retain some foveal cones for decades, leading to the idea that this may be the result of a supplemental cone-specific retinoid recycling pathway. [7] [8] [9] [10] Understanding the relationship between RPE65 and cone photoreceptors is all the more important because cones are responsible for the perception of images in bright light, colors and fine visual details.
Recently, early results of several phase I or I/II LCA2 clinical trials [11] [12] [13] [14] [15] reported a lack of short-term safety concerns (up to 1 year) and modest increases in visual function in young adult patients receiving adenoassociated virus (AAV)-mediated gene replacement therapy. Using chromatic stimuli and light adaptation conditions, Cideciyan et al.
14 were able to isolate both rod and cone photoreceptor contributions to the enhanced visual sensitivity in the retinas of treated patients. It is important to note that treated retinal areas in LCA2 patients do not contain a normal compliment of retinal cells and that these areas may be susceptible to further cell loss due to negative bystander effects from untreated, neighboring degenerate retina. 16 In addition, it has been reported that under conditions of limited chromophore supply, rods and cones compete for RPE65-regenerated 11-cis-retinal. 17 These facts highlight the potential advantages of early intervention and the targeting of retinal islands that contain the maximum compliment of remaining cone photoreceptors.
In spite of the encouraging phase I/II clinical results, important questions remain to be answered regarding AAV-mediated Rpe65 gene therapy. Is gene therapy alone capable of preventing cone photoreceptor degeneration? What is the therapeutic window? How does the presence or absence of rod photoreceptors in treated retinal areas affect the ability of AAV-Rpe65 to restore function to and/or prevent degeneration of cone photoreceptors? Finally, does gene therapy result in sufficient restoration of rod and cone function detectable by an objective functional assay such as electroretinogram (ERG)? These questions are best initially addressed in animal models of the disease for several reasons: first, the currently reported clinical trials evaluated AAV-Rpe65 therapy in young adults or older children whose retinas had already showed extensive degeneration. [11] [12] [13] [14] [15] Second, there are no technologies routinely available to quantify precisely cone photoreceptor densities distant from the fovea in vivo, although this may change in the near future. 18 Currently, only post-mortem microscopic examination of treated eyes would allow for such quantification. The question of how the presence of rod photoreceptors affects therapeutic efficiency in cones is more easily ascertained in Rpe65-deficient animal models because, unlike in LCA2 patients, we have a more complete understanding of the temporal and spatial degeneration patterns of both photoreceptor subtypes. Finally, retinal function, as assessed by full-field ERG is not a sensitive measure of efficacy in treated LCA2 patients due to the relatively small area of retina often transduced with therapeutic vector and the limited fraction of photoreceptors remaining for functional rescue. Multifocal ERG might be useful in this regard, but again, all of these issues can be addressed more directly in animal models of LCA2.
The purpose of this study was to test whether early compared to late delivery of RPE65 would confer functional rescue to cone photoreceptors and or prevent their degeneration in two Rpe65-deficient animal models, the rd12 mouse and the Rpe65 À/À ::Rho À/À double knockout (DKO) mouse. Studies have shown that true conemediated responses in Rpe65-deficient mice are masked by rods with elevated thresholds and altered response kinetics. 19 This provides the rationale for evaluating therapy in the Rpe65 À/À ::Rho À/À mouse, a model that lacks functional rhodopsin, rod outer segments and any rod-mediated light response. This DKO mouse allowed for assessment of pure cone function on Rpe65 gene therapy in the absence of interference from rod-mediated responses. 19 Early intervention was achieved with the use of a quick onset, self-complimentary AAV vector [20] [21] [22] [23] containing human RPE65 cDNA (scAAV5-smCBAhRPE65). ERG, visually evoked behavioral tests and cone-specific immunostaining were used to determine levels of cone preservation on early (P14) and late (P35) vector treatment in the rd12 mouse. The effects of P14 treatment on pure cone function and structure were also evaluated in the Rpe65 À/À ::Rho À/À mouse. Cone loss due to the bystander effects of rod loss 24, 25 in the Rpe65 À/À ::Rho À/À mouse rendered analysis of P35 treatment impossible. Our study results show that AAVmediated gene therapy can restore function to cones and prevent early cone degeneration but only if therapy is initiated before extensive retinal degeneration. In addition, this study suggests that therapy may prove maximally beneficial to cone photoreceptors when it is targeted to retinal islands containing mostly cones and few rods. The results of our study also show that early intervention, using a self-complimentary AAV5 vector, restores substantial visual function within 4 days after treatment. Because progressive cone loss is associated with visual acuity deficits in LCA2 patients, gene therapy may have its greatest impact in young retinas before such cone loss occurs.
Results
Therapy in the rd12 mouse Cone photoreceptor densities are normal in untreated P14 rd12 mice but decrease progressively and in a geographically specific manner. Cone photoreceptor densities in rd12 and C57BL/6J mice were analyzed by staining with peanut agglutinin (PNA), a lectin that selectively labels the interphotoreceptor matrix associated with cone photoreceptors in a variety of species. Comparisons of cone cell counts in PNA-stained retinal whole mounts revealed that there was no significant difference in cone photoreceptor densities between any region of P14 rd12 and P14 wild-type (WT) mice (Figures  1a and c; Table 2; Supplementary Table 1) . Cones are abundant throughout the peripheral and central ( Figures  1b and d ) retinas of both strains at this time point. The black areas in the central retina of P14 rd12 mice ( Figure  1d ) are fragments of adherent retinal pigment epithelium, a layer sometimes difficult to dissociate from neural retina in young rd12 mice. By 5 weeks of age, cone densities have significantly decreased relative to P14, with only a fraction of cones remaining in the dorsal and temporal regions of retina ( Figure 1e ; Table 2; Supplementary Table 1 ). At 5 months, this cone loss now encompassed the entire inferior hemisphere (Figure 1f) , with the remaining cones positive only for M-cone opsin (data not shown).
Rod-mediated ERG is preserved with either P14 or P35 treatment but cone-mediated ERG is only preserved with P14 treatment in rd12 mice. In rd12 eyes treated with scAAV5-smCBA-hRPE65 at P14, restored dark-adapted ERGs were detected as early as 4 days after treatment (Figure 2a ). Both dark-and lightadapted ERGs in animals treated at P14 became stable in amplitude about 2 weeks after treatment (data not shown) and remained so for at least 6 months (the latest time assessed following treatment, Figures 2b and d) . Restoration of dark-adapted ERGs was observed in both eyes treated at early (P14, n ¼ 5) and late (P35, n ¼ 5) (Figures 2b and c) . The average b-wave amplitudes at 0.65 log cd-s per m 2 intensity were 382.38±26.21 (n ¼ 4), 293.86 ± 103.80 (n ¼ 6) and 263.04 ± 81.25 (n ¼ 6) in Self-complementary AAV-mediated cone rescue J Pang et al normal uninjected C57 BL/6J, rd12 eyes treated at P14 and P35, respectively. The b-wave amplitudes in vectortreated rd12 eyes at P14 and P35 were about 76 and 68% of those from uninjected, isogenic normal mice. There was no significant difference between P14 and P35 treatments for both a-wave (P ¼ 0.6688) and b-wave (P ¼ 0.1661) amplitudes. Although dark-adapted ERG responses remained stable and a-and b-wave amplitudes were approximately equivalent in both P14 and P35 treated eyes (Figure 2b ), there was a distinct difference between the restoration of light-adapted ERGs in P14 and P35 treated eyes in the same rd12 animal (Figures 2d, e and f) . With the highest stimulus light intensity (0.65 log cd-s per m 2 ), amplitudes of cone-driven ERG b-waves in P14 treated eyes were significantly restored compared with untreated age-matched rd12 eyes (52.51 ± 13.53 vs 13.00 ± 4.72 mV, P ¼ 0.009), whereas only minimal ERG responses were recorded in the P35 treated eyes (20.73 ± 3.77 vs 13.00±4.72 mV, P ¼ 0.252). Cone b-wave amplitudes of P14 treated eyes (52.51 ± 13.53 mV) were about 60% of normal C57BL/6J mice (87.28±13.06 mV, P ¼ 0.0359) and were significantly larger than those of P35 treated rd12 eyes (20.73 ± 3.77 mV, P ¼ 0.0293).
To test whether early and late treatments affected the sensitivity of the cone system, we measured the implicit time of the cone-driven b-wave. Interestingly, implicit times for the P14 and P35 treated rd12 groups were similar (45.84 ± 1.22 vs 49.52 ± 2.99 ms, P ¼ 0.166), and both showed no difference when compared with the normal C57BL/6J controls (49.80 ± 1.92 ms, P ¼ 0.071 and 0.902, respectively). Both P14 and P35 treatments corrected the delayed implicit time of the cone-driven responses in the rd12 mice (64.00±4.18 ms, P ¼ 0.001 and 0.007, respectively).
To further validate rescue of rod-and cone-mediated responses in vector-treated rd12 eyes, we recorded 10 Hz flicker ERG responses in darkness (Figure 2h) . 19 The amplitude-intensity curve of such a recording protocol presents two peaks that represent the rod-and conedriven responses, respectively (Figure 2i ). At 5 months after treatment, rod-mediated function was restored in both P14 and P35 treated rd12 eyes and the response amplitudes were similar. In contrast, major conemediated responses were restored only in P14 treated eyes (Figures 2h and i) . These results were consistent with those generated with conventional, single-stimulus ERG recordings.
Optomotor behavior reveals the efficacy of scAAV-RPE65 for rescue of both photopic and scotopic vision in the rd12 mouse with P14 treatment, but only scotopic vision with P35 treatment. Optomotor analysis showed that WT mice ( Figure 3 , white bars, n ¼ 4) responded significantly better than rd12 untreated eyes (black bars, n ¼ 3) under all conditions. Under scotopic conditions (Figures 3a and b) , untreated rd12 eyes function poorly with an acuity of 0.079±0.013 cycles per degree (Figure 3a , black bar, mean+s.d., n ¼ 3). C57BL/6J control eyes respond significantly better, showing an acuity of 0.355 ± 0.039 cycles per degree (white bar, n ¼ 4). Rd12 eyes vector treated at P14 have an acuity of 0.370 ± 0.031 cycles per degree (light gray bar, n ¼ 4), a level essentially identical to WT eyes and significantly better than untreated rd12 control eyes (Po0.0001). Eyes treated at P35 responded like C57BL/ 6J eyes under dark-adapted conditions, with an acuity of 0.390±0.080 cycles per degree (dark gray bar, n ¼ 3), and significantly better than their untreated control eyes (black bar, 0.079±0.013, n ¼ 3, P ¼ 0.0026). Statistical comparisons of these measurements are shown in Table 1 .
Scotopic contrast sensitivities (Figure 3b ) paralleled the scotopic acuity results, with eyes treated at P14 (contrast sensitivity of 3.97 ± 0.35, n ¼ 4), and eyes treated at P35 (contrast sensitivity of 4.78±0.49, n ¼ 3) showing contrast thresholds nearly identical to WT mice (4.40±0.74, n ¼ 4). Again, rd12 eyes treated at P14 and P35 performed significantly better than rd12 untreated eyes, which show a contrast sensitivity of 1.05±0.03 (n ¼ 3, Po0.0001 for both comparisons). In all scotopic tests, untreated rd12 eyes perform extremely poorly, essentially equivalent to no rod-mediated visual function.
Under photopic, cone-dominated conditions, C57BL/6J WT control eyes functioned well, showing an average acuity of 0.499±0.39 cycles per degree ( Figure 3c , white bar, n ¼ 4) and average contrast sensitivity of 8.79 ± 2.79 ( Figure 3d , white bar, n ¼ 4). As with scotopic conditions, untreated rd12 mice showed significantly poorer visual acuities and contrast sensitivities than WT C57BL/6J controls, however, untreated rd12 eyes still show Figure 1 Temporal analysis of cone photoreceptor densities in rd12 and wild-type mouse retinas. Fluorescein-isothiocyanate-labeled peanut agglutinin staining revealed that cone photoreceptors were abundant in the central and peripheral regions of the untreated, P14 rd12 mouse retina (c, d), a pattern similar to that seen in the P14, wild-type mouse retina (a, b). Cones degenerate in the rd12 retina by 5 weeks of age (e), remaining only in the dorsal and temporal regions through at least 5 months (f). Arrows: fragments of RPE cells. D, dorsal; V, ventral; T, temporal; N, nasal.
Self-complementary AAV-mediated cone rescue J Pang et al measurable acuities under photopic conditions, a result likely due to the contribution of desensitized rods 20 to visual behavior. Treatment of rd12 eyes at P14 improves acuity (0.481±0.040 cycles per degree, n ¼ 4, P ¼ 0.0091) and contrast sensitivity (9.19 ± 6.93, n ¼ 4, P ¼ 0.022) compared with untreated rd12 eyes (acuity ¼ 0.333± 0.055 cycles per degree and contrast sensitivity of 2.34±0.53, n ¼ 3 each). Treatment at P35 had no statistically significant impact on cone-mediated acuity or contrast sensitivity.
Treatment of rd12 mice at P14 but not at P35 prevents cone degeneration. Five months after the second eye subretinal injection of AAV5-sc-smCBA-hRPE65 vector at P35, rd12 cone densities and opsin profiles were analyzed with PNA, M-cone opsin and S-cone opsin antibody staining. By comparing the number of cone photoreceptors stained with either PNA, MWL or SWL cone opsin, we found no significant differences between cone photoreceptor densities in the four quadrants of P14 treated rd12 and P14 WT retinas (Figures 4a-d; Table  2; Supplementary Table 2A ). In contrast, P35 treated eyes showed significant cone loss relative to P14 treated eyes, again with the exception of the dorsal and temporal quadrants (Figure 4e-h; Table 2; Supplementary Tables  2A and 2B ). There were no significant differences in cone densities between P35 treated and untreated rd12 eyes at 5 months (Figures 4e-h; Table 2; Supplementary Table  2A) . Residual cones in P35 treated rd12 retinas stained positive for M-cone but not S-cone opsin (Figures 4g  and h ).
Therapy in the Rpe65
À/À ::Rho À/À mouse Cone photoreceptor densities are normal in untreated P14 but not untreated P35 Rpe65 À/À ::Rho À/À mice.
Peanut agglutinin staining of retinal whole mounts revealed that there was no significant difference in cone photoreceptor densities in any quadrant of untreated P14 Figure 2 Comparison of rod-and cone-driven functions in rd12 mice after early P14 or late P35 subretinal deliveries of a scAAV5-smCBAhRPE65 vector. The left, middle and right columns show dark-adapted, light-adapted and 10 Hz flicker electroretinograms (ERGs), respectively. P14 treatment resulted in functional rescue to rod system as early as 4 days after injection (a). Representative dark-adapted ERGs recorded at 6 or 5 months after P14 (left eye) and P35 (right eye) treatment showed robust restoration of the rod system functions (b and c), as indicated by significant increases of both a-and b-wave amplitudes (c) relative to untreated controls that had minimal responses. For the light-adapted ERG, P14 treatment significantly improved the b-wave amplitudes to a level about 60% of normal uninjected controls (d, e and f); whereas P35 treatment did not result in significant b-wave amplitude increase compared to untreated rd12 mice (f). Light-adapted ERG showed that both P14 and P35 treatments significantly reduced the delayed b-wave implicit time to normal levels (g). Both representative (h) and statistical (i) data from 10 Hz flicker ERGs.
Self-complementary AAV-mediated cone rescue J Pang et al Figure 3 scAAV-RPE65 treatment restores photopic vision in rd12 mice treated at P14, and scotopic vision in rd12 mice treated at P14 or P35. Under scotopic conditions, treatment with AAV-RPE65 at P14 (light gray bar, n ¼ 4 eyes and at P35 (dark gray bar, n ¼ 3 eyes) leads to acuities (a) and contrast sensitivities (b) comparable to uninjected C57BL/6 mice (white bars, n ¼ 4 eyes). Untreated rd12 eyes (black bars, n ¼ 3) perform significantly poorer in tests of both scotopic acuity (a) and scotopic contrast sensitivity (b) than those from C57 or treated rd12 eyes. The level of vision in these untreated eyes is equivalent to no visual function. Under photopic conditions, (c) rd12 mouse eyes treated with AAV-RPE65 at P14 (light gray bar, n ¼ 4) have significantly better acuity than untreated rd12 control eyes (black bar, n ¼ 3) and maintain photopic acuity comparable to wild-type C57BL/6J eyes (white bar, n ¼ 4), whereas eyes treated at P35 (dark gray bar, n ¼ 3 eyes) show no significant change from their untreated rd12 counterparts (black bar, n ¼ 3 eyes). (d) As with photopic contrast sensitivity, rd12 eyes treated at P14 (light gray bar, n ¼ 4 eyes), but not those treated at P35 (dark gray bar, n ¼ 3 eyes) show photopic contrast sensitivity near wild-type C57BL/6J levels (white bar, n ¼ 4 eyes). Under scotopic conditions, P14 and P35 treatment produces acuity and contrast sensitivity similar to wild-type animals and wild-type, P14 treated and P35 treated eyes all have significantly better acuity and contrast sensitivity than untreated rd12 eyes. Under photopic conditions, only P14 treated eyes are not significantly different from wild-type eyes; P35 treatment eyes did not differ significantly from rd12 untreated eyes for both photopic acuity and contrast sensitivity. Each mouse was tested for 4-6 trials per condition. Data from each animal (n ¼ 3-4) were then averaged to obtain the means for each condition. The standard deviation listed is the standard deviation of the individual mouse means. P-values were calculated using an unpaired two-tailed t-test. ***Po0.001, **Po0.01, *Po0.05. Table 2; Supplementary Table 3A) . Cones appear throughout the peripheral and central retinas at this age. By 5 weeks, cone densities have significantly decreased relative to P14 Rpe65 À/À ::Rho À/À mice ( Figure 5c ; Table 2; Supplementary Table 3A) with only a few cones remaining in the dorsal and temporal regions of the retina (Figure 5c ), a pattern similar to that observed in the untreated, P35 rd12 mouse (Figure 1e) . Table 2; Supplementary Table  3A) . M-cone opsin and S-cone opsin antibody staining revealed that both pigments were present in preserved Figure 4 Retinal whole mounts of rd12 mice treated at P14 (left column) or P35 (right column) with scAAV5-hRPE65 and stained with peanut agglutinin (PNA), MWL cone opsin antibody or SWL cone opsin antibody. PNA staining revealed that cones were abundant in the peripheral (a) and central (b) regions of the P14 treated rd12 retina. P14 treated cones were positive for both MWL (c) and SWL cone opsins (d). Cone-specific PNA staining after P35 treatment was reduced centrally (f) and was restricted to dorsal and temporal regions of retina (e), a pattern similar to that seen in the P35 untreated, rd12 retina. P35 treated cones contained MWL cone opsin (g), but lacked detectable SWL cone opsin (h). D, dorsal; V, ventral; T, temporal; N, nasal. 
Discussion
Documentation of cone loss in rd12 retinas with PNA lectin revealed that the optimal treatment age in this model is P14. At this age, cone densities remained near normal in both central and peripheral regions of retina. Cone degeneration became obvious in rd12 mice older than 3 weeks. By P35, significant cone loss had occurred in untreated rd12 eyes, an observation similar to that seen in other Rpe65-deficient models. 2, 26, 27 Here we show that early (P14) treatment of rd12 mice with a quick-onset, self-complimentary (scAAV) vector containing the human Rpe65 cDNA restores ERG responses and visually evoked behavior to both rod and cone photoreceptors and prevents both MWL-and SWL-containing cone degenerations for at least 6 months. These results are Self-complementary AAV-mediated cone rescue J Pang et al consistent with and extend previous findings that both lentiviral-and adenoviral-mediated RPE65 expression levels confer rescue to cones in the Rpe65 À/À mouse that carries a different, null mutation. 28, 29 Recovered lightadapted responses imply restoration of cone pigment kinetics. Although the precise kinetics of cone adaptation by ERG was not studied in this work, it would be of interest because it may represent another useful parameter of cone health after gene therapy. In contrast, treatment delayed by just 3 weeks still rescued rods functionally and by acuity/contrast sensitivity, a result not seen for cones. This is one of the first studies to show the advantages of scAAV over classic AAV vectors in terms of its ability to restore function more rapidly in a retinal degenerative model while further confirming earlier reports of its ability to elicit more rapid transgene expression. [20] [21] [22] [23] Like classic serotype 5 AAV, scAAV5-mediated transgene expression is not limited to the RPE. Regardless, we observed therapeutic transgene expression mainly located within RPE cells, 23 the key cellular target for rod and cone rescue. When using standard AAV vectors, it is typically necessary to wait 1 month post-injection to evaluate therapeutic efficacy. Bearing in mind that, in terms of biological time, 1 month of a mouse's life corresponds to approximately several years of human life, these results have important implications for ongoing LCA2 clinical trials by suggesting that early intervention may increase the chance of preserving cone photoreceptors and restoring cone function to these patients. 30 However, precisely how this short window of therapeutic response in mice relates to the human condition remains to be determined.
The possibility that desensitized rods may have contributed to the ERG and behavioral results we attributed to rescued cone function in P14 vector-treated rd12 mice is not supported by analysis of analogous treatment in 'cone-function-only' Rpe65 À/À ::Rho À/À DKO mice. Because rods in this animal lack rhodopsin, there can be no rod phototransduction and hence no rod source of light-elicited electrical activity to confound ERG analysis. Although this experiment is similar to a study in which lentiviral-mediated Rpe65 therapy was administered to the Rpe65 À/À /Gnat1a À/À mice that also lack rod function due to a mutation in rod transduction, 28 our study uses AAV, a well-characterized viral vector with documented clinical safety in the retina [11] [12] [13] [14] [15] and with different tropism and transduction characteristics than lentivirus. We observe cone rescue at all levels of analysis with P14 treatment of the Rpe65 ::Rho À/À mice were unsuccessful (data not shown). The inability to reexamine the question of a window of therapy in the Rpe65 À/À ::Rho À/À mouse was likely due to the fact that cones in this DKO model have extensively degenerated before 1 month of age. 2 In addition, rods in rhodopsin-deficient mice begin to degenerate within 1 month of life, 31, 32 which leads to cone degeneration at least partially through reduction in a rod-derived cone viability factor, RdCVF. 25 Thus, cone and rod degeneration and perhaps other structural or biochemical abnormalities that accompany early photoreceptor cell death [33] [34] [35] preclude analysis of late (P35) AAV vector-mediated cone therapy in Rpe65 À/À ::Rho À/À mice. Nevertheless, cone rescue as seen in the P14-treated rd12 model was confirmed in a retina having only cone function.
Our study results are consistent with earlier findings that cone cell death in Rpe65-deficient animal models proceeds in a rapid, cone subtype-dependent manner; SWL cones degenerating faster than MWL cones. 2, 26, 27 In support, analysis of LCA2 patients also reported differences in chromatic sensitivities between long-and shortwavelength light: only human LWL cone function was detectable in LCA2 patients carrying various Rpe65 mutations, SWL cone function being undetectable. 5 Despite the fact that murine retinas lack true LWL cones, it is worth noting that SWL cones still appear to be the most sensitive to Rpe65 deficiency across species. In another study, it was shown that cone opsin mislocalization in the Rpe65 À/À ::Rho À/À was corrected with systemic administration of 11-cis retinal. 2 This correction was more pronounced in MWL than in SWL cones. The reasons that SWL cones appear to be more adversely affected by chromophore depletion remain to be elucidated. It is possible that type-specific differences in opsin stability in the absence of chromophore could have a role in cone survival. It is known, for example, that glycosylation is not required for the formation of functional bovine MWL cone pigment, 36 suggesting that there are intrinsic structural differences between MWL and SWL opsins despite their amino-acid sequence similarities. Perhaps MWL cone opsin in the absence of 11-cis retinal is slightly more stable than SWL opsin leading to a slower rate of accumulation of misfolded MWL opsin aggregates and a slower rate of MWL cone cell death. Here we show that AAV-RPE65 therapy is capable of preserving both cone photoreceptor subtypes as long as therapy is initiated before extensive cone degeneration. The differential ability of this therapy to preserve one cone subtype over another, although not yet evaluated in LCA2 patients, [11] [12] [13] [14] [15] deserves further examination.
To compare overall functional differences (ERG and optomotor) following P14 and P35 treatment in eyes that had received comparable vector coverage of their retinas, we only chose rd12 mice in which both eyes showed similar levels of retinal detachment following subretinal vector injection. This method for selecting equivalently treated pairs of partner eyes is validated by the similar rod-related ERG amplitudes seen in both P14 and P35 treated eyes (Figure 2b ). Mice used in this study had 60-80% retinal detachments in both eyes after injection, and this level of vector treatment corresponds well to the level of ERG restoration seen (Figure 4e ). Experiments are ongoing to test whether MWL cone function can be restored after P35 treatment when that small dorsal area of remaining MWL cones is specifically targeted by vector injection.
Although ERG recordings in the rd12 and Rpe65
À/À
:: Rho À/À mice cannot be directly compared because they were taken at different institutions, we believe it is interesting to note that cone-mediated ERG responses in Rpe65 À/À ::Rho À/À mice were higher than responses in rd12 mice at the same stimulus intensity (0.7 log cd-s per m 2 ). This result is consistent with a recent finding that under conditions of limited chromophore supply, rods and cones Self-complementary AAV-mediated cone rescue J Pang et al compete for RPE65-regenerated 11-cis-retinal. 17 Rods, because of their higher number, proximity to the RPE as a chromophore source and the instability of cone opsins relative to rhodopsin, have advantage under this condition. Interestingly, it is specifically the absence of rhodopsin (and not simply the absence of rod outer segments) that allows cones to benefit from the availability of more 11-cis-retinal. It is understandable, therefore, that we observed a difference in cone-mediated responses between these two animal models. Put simply, both rods and cones compete for gene therapy-derived chromophore in the rd12 mouse, whereas in the Rpe65 :: Rho À/À mice were still B60% of their isogenic control (Rho À/À mice), a value similar to that seen when comparing ERG responses of treated rd12 mice to WT controls. This is due to the fact that Rho À/À mice show 'supernormal' cone ERGs, 37 a phenomenon that may also be attributed to cones in these mice existing as the sole beneficiary of 11-cis-retinal. These observations support delivery of clinical vector to central, cone-rich retinal regions of young LCA2 patients while attempting to minimize surgical manipulation of the macula. It is in these relatively cone-rich and rod-poor regions where chromophore 'theft' is likely to be minimal and therefore where cones might benefit most from a vector-enhanced pool of 11-cis-retinal.
In summary, our study results show that AAVmediated gene therapy prevents cone photoreceptor degeneration and preserves cone function in two genetically distinct models of Rpe65-LCA, the rd12 and the Rpe65 À/À ::Rho À/À mouse. Clearly however, vector must be administered before extensive cone degeneration. In addition, we show that functional recovery in the rd12 mouse, a model for human LCA2, is measurable within 4 days of treatment with a self-complimentary, serotype 5 AAV vector expressing RPE65. With knowledge that phase I LCA2 clinical trials presently show no short-term safety concerns [11] [12] [13] [14] [15] as well as significant and quantifiable visual improvements, 14, 15 this study supports the extension of human LCA2 trials into patients showing less extensive retinal degeneration, particularly young patients who may have the most to gain from this therapy because they are more likely to retain significant central cone photoreceptor densities.
Materials and methods

Animals
C57BL/6J mice and the congenic inbred strain of rd12 mice 38 were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Rpe65 
scAAV5-smCBA-hRPE65 vector
Pseudotyped AAV5 capsid, self-complementary AAV vectors (scAAV) were used in this study as they have been shown to be more efficient vectors for transduction of retina than standard, single-stranded AAV vectors. [20] [21] [22] [23] The scAAV5-smCBA-hRPE65 vector contains the small, hybrid cytomegalovirus-chicken b-actin (smCBA) promoter that has been shown to have identical transduction and tropism characteristics to full chimeric cytomegalovirus-chicken b-actin (CBA) promoter when targeted to the mouse retina. 39 The corresponding vector plasmid for scAAV5-smCBA-hRPE65 was constructed by replacing the humanized green fluorescent protein (GFP) cDNA of sc-trs-smCBA-hGFP with the human RPE65 cDNA, through a NotI digest. Both contain flanking AAV serotype 2 inverted terminal repeats; one inverted terminal repeat has modifications required for packaging as a selfcomplimentary AAV vector. 40 Vectors were generated and purified by previously described methods. 41 Vector titer was determined by real-time PCR and final aliquots were resuspended in balanced salt solution (Alcon Laboratories, Forth Worth TX, USA) containing 0.014% Tween 20.
Subretinal injections
scAAV5-smCBA-hRPE65 vector (1 ml, 3.9 Â 10 10 delivered vector genomes) was injected subretinally into the left eyes of each P14 rd12 mouse (n ¼ 5) and in the right eye 3 weeks later (P35). The same concentration of vector was injected subretinally into the right eyes of each P14 Rpe65 À/À ::Rho À/À mouse (n ¼ 5). Subretinal injections were performed as previously described. 42, 43 Further analysis was carried out only on mice that received comparable, successful injections (460% retinal detachment and minimal complications). We chose only rd12 mice, in which both eyes showed similar retinal detachments and Rpe65 À/À ::Rho À/À mice with equally comparable unilateral detachments after subretinal injections for further analysis. It is well established that the area of retinal detachment corresponds to area of viral transduction. 14, 44 Electroretinographic analysis Electroretinograms of rd12 mice were recorded using protocols modified from previous studies. 20, 45, 46 Briefly, mice were dark adapted overnight and anesthetized with a mixture of ketamine (75 mg kg À1 intramuscularly) and xylazine (13.6 mg kg À1 intramuscularly). Pupils were dilated with 1% tropicamide and 2.5% phenylephrine hydrochloride, and a heating pad was used to keep the body temperature at 38 1C. The corneal electrode was a gold wire loop; a reference electrode was placed on the forehead and a ground electrode was applied subcutaneously near the tail. Signals were amplified at 10 000 gain and bandpass filtered between 0.1 and 1000 Hz. The signals were digitized at 5.12 kHz for conventional ERG with a data acquisition device (National Instrument, Austin, TX, USA). To increase the signal-noise ratio, we averaged 3-6 signals for conventional dark-adapted ERG; whereas 12-16 signals were averaged for lightadapted responses using a custom-compiled program (LabView 7.1; National Instrument).
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Ganzfeld illumination used a Grass PS22 Xenon visual stimulator (Grass Instrument Inc., West Warwick, RI, USA). The light flash had duration of 10 ms, and the maximum intensity was 0.65 log cd-s per m 2 . A timer (Uniblitz, Rochester, NY, USA) was used to control the frequency of the flash. In dark-adapted ERG recordings, the interstimulus interval was at least 12 s for low intensities and more than 30 s for high intensities. For light-adapted ERG recordings, a background light of 30 cd per m 2 was applied to suppress rod responses. The stimulus light intensity was attenuated with neutral density filters (Kodak, Rochester, NY, USA) and luminance was calibrated with an IL-1700 integrating radiometer/photometer (International Light, Newburyport, MA, USA).
Electroretinograms of Rpe65 À/À ::Rho À/À mice and rd12 mice 4 days after P14 treatment were recorded using a UTAS Visual Diagnostic System with a Big Shot Ganzfeld (LKC Technologies, Gaithersburg, MD, USA). Mice were dark adapted, anesthetized and dilated similar to methods used for rd12 mice. Gold wire loop electrodes were placed on each cornea and a reference electrode was placed near the nose. Dark-adapted ERGs of the rd12 mouse 4 days after P14 treatment were applied at 0.4 log cd-s per m ::Rho À/À mice (both treated and untreated eyes) were averaged and used to generate standard errors. These data were imported into Sigma Plot for final graphical presentation.
ERG data are presented as mean ± s.d. Statistical significance was examined with analysis of variance. Pair-wise comparisons between groups for the ERG were performed by the Bonferroni post hoc test. A P-value of less than 0.05 was considered as statistically significant.
Optomotor testing
Photopic and scotopic visual acuities and contrast sensitivities of treated and untreated mouse eyes were measured using a two-alternative forced choice paradigm as described previously 47, 48 with minor modifications. To separately test the sensitivity of each eye from the same animal, we took advantage of the fact that mouse vision has minimal binocular overlap and that the left eye is more sensitive to clockwise rotation and the right to counterclockwise rotation. 49 Thus in our 'randomize-separate' optomotor protocol, acuities or contrast sensitivities for each eye were determined separately, with correct detection of patterns rotating in the clockwise direction vision being detected by the left eye and correct responses in the counterclockwise direction being driven primarily by visual signals originating from the right eye. Thresholds for each eye were determined simultaneously through stepwise functions for correct responses in both the clockwise and counterclockwise directions. Acuity was defined the highest spatial frequency (100% contrast) yielding a threshold response, and contrast sensitivity was defined as 100 divided by the lowest percent contrast (pattern of 0.256 cycles per degree) yielding a threshold response. For both photopic and scotopic acuities, the initial stimulus was a 0.200 cycles per degree sinusoidal pattern with a fixed 100% contrast. For photopic contrast sensitivity measurements, the initial pattern was presented at 100% contrast, with a fixed spatial frequency of 0.256 cycles per degree. For scotopic contrast sensitivity measurements, the spatial frequency was fixed at 0.031 cycles per degree, a spatial frequency tuned for rod vision. 47 All patterns were presented at a speed of 12 degrees per second. Photopic vision was measured at a mean luminance of 70 cd per m 2 . For scotopic measurements, mice were dark adapted overnight and light levels were attenuated to 3.5 Â 10 À5 cd per m 2 through the use of neutral density filters. Visual acuities and contrast sensitivities were measured for both eyes of each mouse 4-6 times over a period of 1-2 weeks. WT control animals were 6 months old at testing time (n ¼ 4), and P14 treated animals were at least 6 months old (n ¼ 4). Untreated eyes from 6-month rd12 mice (n ¼ 3), opposite from those that received treatment at P35 (n ¼ 3), are presented as the untreated group in bar graphs. Unpaired t-tests were carried out on acuity and percent contrast values to determine significance of results.
Tissue preparation and immunohistochemistry
Eyes of P14 and P35 treated rd12 mice were enucleated at 6 and 5 months of age, respectively. For comparison, eyes of untreated rd12 mice were enucleated at 2 weeks, 5 weeks and 5 months of age. Eyes of P14 treated and untreated Rpe65 À/À ::Rho À/À mice were enucleated at P42. Eyes of control C57BL/6J were enucleated at 2 weeks of age. Retinal whole mounts were prepared according to previously described methods. 50, 51 Briefly, immediately following killing, the limbus of injected and uninjected eyes was marked at 12-o'clock position with a burned needle facilitating orientation. The eyes were then enucleated and fixed in 4% paraformaldehyde. Cornea, lens, vitreous and retinal pigment epithelia were removed from each eye without disturbing the retina. Fixed retinal whole mounts were washed in 1 Â phosphate-buffered saline (PBS) and incubated in blocking solution (2% normal goat serum, 0.3% Triton X-100 in 1% bovine serum albumin in PBS) for 30-60 min at room temperature. Samples were washed one time briefly with 0.3% Triton X-100 and 1% bovine serum albumin in PBS and then incubated for 24-48 h in the dark at 4 1C with either S-or M-cone opsin primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:500 in 0.1% Triton X-100 and 1% bovine serum albumin in PBS. After incubation in primary antibodies, whole mounts were rinsed with PBS and incubated in the dark at 4 1C overnight in IgG secondary antibodies tagged with either Alexa 594 or Alexa 488 fluorophore (Molecular Probes, Eugene, OR, USA) diluted 1:500 in PBS. Whole mounts were rinsed with 1 Â PBS and then incubated in fluorescein-isothiocyanate-conjugated PNA diluted 1:100 in 10% normal goat serum at 4 1C overnight, in the dark. After a final rinse with 1 Â PBS, whole mounts were oriented on slides with the superior (dorsal) ::Rho À/À mice. These values were obtained using high magnification images ( Â 10) of the whole mounts shown in Figures 1, 4 , 5 and 7 as well as P14 WT retinas stained for MWL and SWL cone opsins ( Â 10; images not shown). Five squares (500 mm 2 ) were placed over identical areas of each central retina and four respective quadrants (total squares per retinal whole mount ¼ 25). The squares were placed at a minimum of 6000 mm from the optic disk in all four peripheral quadrants. Cone photoreceptors were counted in each respective retinal area, values were averaged and standard deviations were calculated. The standard t-test was used to calculate P-values between desired samples. Significant difference was defined as a P-value o0.05. Data are presented in Table 2 and Supplementary Tables  1, 2A , 2B, 3A and 3B. As an additional measure of cone cell preservation, we also performed a similar analysis using measurements of fluorescence intensity. The results were the same (data not shown). Supplementary information is available at Gene Therapy's website.
